Posted by Michael Wonder on 17 Nov 2021
Zentalis Pharmaceuticals announces fast track designation granted by the U.S. FDA to ZN-c3 for the treatment of uterine serous carcinoma
17 November 2021 - Zentalis Pharmaceuticals today announced that the U.S. FDA has granted fast track designation to ZN-c3, the Company’s oral WEE1 inhibitor product candidate, for the treatment of recurrent or persistent uterine serous carcinoma in adult women.
ZN-c3 is a potentially first in class and best in class oral inhibitor of WEE1 in development for the treatment of advanced solid tumours.
